KROS stock news · Keros Therapeutics, Inc.
Get alerts for KROS
Follow Keros Therapeutics, Inc. (KROS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for KROSFree on the App Store and Google Play, or on the web.
Keros Therapeutics will buy back up to $5 million in its own stock after getting $20 million from Takeda.
Good for KROSKeros approved up to $5 million in share purchases after receiving a $20 million Takeda payment. It expects cash to cover planned costs into 2029, supporting its outlook.